Amarin Corporation(US:AMRN) Newsfilter·2024-04-06 19:30Core Insights - Amarin Corporation presented findings on the efficacy of VASCEPA/VAZKEPA in reducing Major Adverse Cardiovascular Events (MACE) in patients with varying Lipoprotein(a) [Lp(a)] levels and irrespective of baseline LDL-C levels [1][2][4] Group 1: Efficacy of VASCEPA/VAZKEPA - The analysis showed that high Lp(a) concentrations correlate with increased cardiovascular event risk, even when LDL-C levels are managed [2][4] - In a post hoc analysis of the REDUCE-IT study, 7,026 patients were evaluated, revealing a significant relationship between baseline Lp(a) levels and MACE risk, independent of LDL-C and triglycerides [3][4] - Icosapent ethyl (IPE) demonstrated a relative risk reduction of 21% for patients with Lp(a) ≥50 mg/dL and 25% for those with Lp(a) <50 mg/dL [5][4] Group 2: LDL-C and Cardiovascular Outcomes - The study also assessed the impact of IPE on cardiovascular outcomes among patients with different baseline LDL-C levels, specifically those below and above 55 mg/dL [6][7] - Among patients with LDL-C <55 mg/dL, the primary outcome rate was 16.2% in the IPE group compared to 22.8% in the placebo group, indicating a hazard ratio (HR) of 0.66 [7] - For patients with LDL-C ≥55 mg/dL, the rates were 17.4% in the IPE group versus 21.9% in the placebo group, with an HR of 0.76, showing consistent efficacy across both LDL-C subgroups [7][8] Group 3: Study Background and Significance - The REDUCE-IT study was a global cardiovascular outcomes trial involving 8,179 patients, designed to evaluate the effect of VASCEPA in high-risk patients with controlled LDL-C levels [10][11] - The findings reinforce the clinical benefit of IPE in reducing cardiovascular events, particularly in patients with elevated triglycerides and varying Lp(a) levels [5][8] - Amarin aims to enhance the understanding of cardiovascular risk management beyond traditional therapies, emphasizing the importance of ongoing research in this area [2][9]